Education
About Us
Working with TipRanks
Follow Us
Modalis Therapeutics Corporation (JP:4883)
:4883
4883 Stock Chart & Stats
¥56.00
-¥3.00(-2.91%)
At close: 4:00 PM EST
¥56.00
-¥3.00(-2.91%)
Day’s Range― - ―
52-Week Range¥52.00 - ¥119.00
Previous CloseN/A
Volume5.80M
Average Volume (3M)719.68K
Market Cap
¥4.99B
Enterprise Value¥1.34B
Total Cash (Recent Filing)¥3.26B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.20
Next Earnings
May 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.95
Shares Outstanding87,484,100
10 Day Avg. Volume617,120
30 Day Avg. Volume719,680
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.33
Price to Sales (P/S)0.00
P/FCF Ratio-3.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Leverage / No Debt In 2024Reported no debt in 2024 and positive equity provide a conservative capital structure that lowers default risk and gives flexibility to fund R&D or negotiate partnerships. A low-leverage base is a durable buffer during prolonged development cycles common in biotech.
Platform Approach Targeting Regulatory Genomic RegionsA platform focused on modulating gene expression via regulatory genomic regions creates a scalable discovery engine. This can generate multiple programs, attract partnerships, and create intellectual property barriers — structural advantages if scientific validation advances in clinical stages.
2024 Cash Burn Improved Versus 20232024 cash burn improvement versus 2023 suggests better cost control or milestone-driven progress. If management sustains lower cash consumption, runway extends and near-term financing need eases, giving more time to reach clinical inflection points or secure partnerships without immediate dilution.
Bears Say
Revenue Fell To Effectively Zero In 2023–2024Revenue collapsing to effectively zero removes internal funding and indicates no commercialized products. Over the medium term this forces reliance on external capital or partnerships, increasing dilution and reducing strategic flexibility if commercialization visibility remains absent.
Consistent Negative Operating And Free Cash FlowPersistent negative operating and free cash flow from 2020–2024 highlights ongoing cash burn to fund development programs. Long-term, sustained negative cash conversion erodes reserves, necessitates frequent financing, and constrains the company’s ability to invest in multiple programs or weather development delays.
Sustained Large Net Losses Since 2020The shift from profitability in 2019 to sustained large losses through 2024 produces negative returns on equity and risks capital erosion. Continued losses weaken bargaining power with partners and investors and raise questions about long-term viability absent clear clinical successes or new funding sources.
Modalis Therapeutics Corporation News
4883 FAQ
What was Modalis Therapeutics Corporation’s price range in the past 12 months?
Modalis Therapeutics Corporation lowest stock price was ¥52.00 and its highest was ¥119.00 in the past 12 months.
What is Modalis Therapeutics Corporation’s market cap?
Modalis Therapeutics Corporation’s market cap is ¥4.99B.
When is Modalis Therapeutics Corporation’s upcoming earnings report date?
Modalis Therapeutics Corporation’s upcoming earnings report date is May 13, 2026 which is in 86 days.
How were Modalis Therapeutics Corporation’s earnings last quarter?
Modalis Therapeutics Corporation released its earnings results on Feb 12, 2026. The company reported -¥3.95 earnings per share for the quarter, missing the consensus estimate of N/A by -¥3.95.
Is Modalis Therapeutics Corporation overvalued?
According to Wall Street analysts Modalis Therapeutics Corporation’s price is currently Overvalued.
Does Modalis Therapeutics Corporation pay dividends?
Modalis Therapeutics Corporation does not currently pay dividends.
What is Modalis Therapeutics Corporation’s EPS estimate?
Modalis Therapeutics Corporation’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Modalis Therapeutics Corporation have?
Modalis Therapeutics Corporation has 87,484,100 shares outstanding.
What happened to Modalis Therapeutics Corporation’s price movement after its last earnings report?
Modalis Therapeutics Corporation reported an EPS of -¥3.95 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.724%.
Which hedge fund is a major shareholder of Modalis Therapeutics Corporation?
Currently, no hedge funds are holding shares in JP:4883
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Modalis Therapeutics Corporation
Modalis Therapeutics Corporation engages in the research and development of therapeutics to treat patients with serious genetic disorders. It is developing therapies for genetic diseases using its proprietary CRISPR-GNDM technology that enables to control gene expressions through modulating the switch (epigenetics of a specific locus. The company has a. joint research agreement with JCR Pharmaceuticals Co., Ltd. to evaluate the drug delivery technology of the gene therapy to the central nervous system (CNS) assuming CNS diseases as a target. The company was formerly known as EdiGENE Corporation and changed its name to Modalis Therapeutics Corporation in August 2019. Modalis Therapeutics Corporation was founded in 2016 and is headquartered in Tokyo, Japan.
Technical Analysis
Solasia Pharma KK
―
Nippon Chemiphar Co., Ltd.
―
Symbio Pharmaceuticals Limited
―
Medrx Co., Ltd.
―
Cyfuse Biomedical K.K.
―